Lipids

CL4F8-6 is an ionizable lipid with a pKa of 6.14. Researchers have utilized it in conjunction with other lipids to formulate lipid nanoparticles (LNPs).

Lipid 8 is an ionizable lipid contributing to creating lipid nanoparticles (LNPs). These LNPs, which incorporate polo-like kinase 1 (Plk1) siRNA, effectively trigger apoptosis in U266 multiple myeloma cells.

An ionizable lipid featuring symmetric branched lipid tails and a propanolamine polar head group. Lipid III-45 has specifically been used to encapsulate mRNA and may be used for similar delivery applications. Reagent grade, for research purpose.

YK-009 is an ionizable lipid with a pKa of 6.51. It has been utilized alongside other lipids to create lipid nanoparticles (LNPs). When SARS-CoV-2 Omicron variant mRNA is administered within YK-009-containing LNPs, it stimulates the production of IgG antibodies that specifically bind to the receptor-binding domain (RBD) of the virus.

A multichargeable ionizable lipid featuring biodegradable ester and carbonate linkages. Additional features include two alkynyl branches and a cis-unsaturated lipid core. This compound may be used in the formulation of lipid nanoparticles (LNP's) for drug delivery applications. Reagent grade, for research purpose.

C14-SPM serves as a polyamine branched-chain lipidoid used in the development lipid nanoparticles (LNPs) for siRNA delivery.

Lipid A4 is a multi chargeable lipid used in generating lipid nanoparticles (LNPs) for mRNA delivery. These LNPs selectively accumulate in the uterus, placenta, ovaries, and spleen, as well as the liver in pregnant mouse dams, unlike LNPs containing C12-200.

A12-Iso5-2DC18 is an unsaturated ionizable lipid employed in creating lipid nanoparticles (LNPs). These LNPs, which encapsulate mRNA encoding luciferase, have been utilized to stimulate luciferase expression in HeLa cells.

Lipid 202 represents an innovative ionizable lipid specifically designed for the delivery of RNA. Its unique properties make it a promising candidate for advancing RNA-based therapeutics.